CN103800885B - Medicinal composition for treating oral fungal infection, preparation method and application thereof - Google Patents
Medicinal composition for treating oral fungal infection, preparation method and application thereof Download PDFInfo
- Publication number
- CN103800885B CN103800885B CN201410069103.3A CN201410069103A CN103800885B CN 103800885 B CN103800885 B CN 103800885B CN 201410069103 A CN201410069103 A CN 201410069103A CN 103800885 B CN103800885 B CN 103800885B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- rhizoma
- weight
- parts
- fungal infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a medicinal composition for treating oral fungal infection. The medicinal composition comprises the following raw materials in parts by weight: 10-45 parts of poria, 5-40 parts of dandelion, 5-40 parts of bighead atractylodes rhizome, 5-40 parts of rhizoma atractylodis, 5-40 parts of musk, 5-40 parts of processed pinellia tuber, 3-30 parts of dried tangerine peel, 3-30 parts of notopterygium root, 3-30 parts of ligusticum wallichii, 1-10 parts of raw ginger, 1-10 parts of ginseng and 1-20 parts of nidus vespae. The invention also provides a preparation method and particular application of the medicinal composition. Pharmacodynamic tests prove that the medicinal composition has strong antibacterial activity to candida albicans, candida albicans, aspergillus, mucor, cryptococcus and other fungi, and has a good treatment effect to patients infected with oral fungi. The medicinal composition has the advantages of good curative effect, small irritation, small side effect and low administration cost, is suitable for large-scale popularization and use, and has a good medical prospect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of fungal infection, especially relate to a kind for the treatment of and alleviate pharmaceutical composition of buccal cavity fungal infection and its production and use, belong to technical field of Chinese medicines.
Background technology
The modal pathogenic bacterium of buccal cavity fungal infection are Candida, and wherein the pathogenicity of candida albicans bacterium and Candida tropicalis is the strongest, are also the modal pathogenic bacterium of Candida.Buccal cavity fungal infection can betide any position in oral cavity, as lip, tongue, soft palate, hard palate, tonsil, palate hang down, gingiva and pharyngeal.Often show as swelling pain discomfort, ulcer and erythema and parageusia and the oral mucosa hypertrophy etc. of inflammation part.Mycosis has stronger infectiousness, can be widely current, and along with the application of antibiotic and immunosuppressive drug, buccal cavity fungal infection presents the trend rising gradually in recent years.Often select Oral antifungal agents thing nystatin, amphotericin B, Caspofungin and flucytosine etc. for buccal cavity fungal infection doctor trained in Western medicine, except oral drugs, usually coordinate sodium bicarbonate, aldrich mixture to carry out topical therapeutic.
Obtain clinically certain therapeutical effect for above-mentioned conventional antifungal agent, but also there is many side effect, can cause that intestines and stomach dysfunction, leukocyte, blood platelet reduction and transaminase raise etc., and novel antifungal agent as novel three she Qu Kang of class medicine sound of crying or vomiting, fluoro three class medicine fluconazol etc. have overcome side-effect problem, but price is all comparatively expensive, is difficult to be widely used on a large scale.To this, in New Drug Research technical field, increasing research institution using Chinese medicine compound with low cost as important research and development emphasis to finding determined curative effect the comparatively cheap new drug of cost.
Summary of the invention
The object of the invention is to solve the deficiencies in the prior art, the pharmaceutical composition of a kind of determined curative effect, treatment buccal cavity fungal infection with low cost is provided, this pharmaceutical composition is made up of following raw material and weight ratio:
Poria 10-45 weight portion, Herba Taraxaci 5-40 weight portion, Rhizoma Atractylodis Macrocephalae 5-40 weight portion, Rhizoma Atractylodis 5-40 weight portion, Herba Pogostemonis 5-40 weight portion, Rhizoma Pinelliae Preparatum 5-40 weight portion, Pericarpium Citri Reticulatae 3-30 weight portion, Rhizoma Et Radix Notopterygii 3-30 weight portion, Rhizoma Chuanxiong 3-30 weight portion, Rhizoma Zingiberis Recens 1-10 weight portion, Radix Ginseng 1-10 weight portion, Nidus Vespae 1-20 weight portion.
Preferably, Poria 15-40 weight portion, Herba Taraxaci 8-35 weight portion, Rhizoma Atractylodis Macrocephalae 8-35 weight portion, Rhizoma Atractylodis 8-35 weight portion, Herba Pogostemonis 8-35 weight portion, Rhizoma Pinelliae Preparatum 8-35 weight portion, Pericarpium Citri Reticulatae 5-25 weight portion, Rhizoma Et Radix Notopterygii 5-25 weight portion, Rhizoma Chuanxiong 5-25 weight portion, Rhizoma Zingiberis Recens 2-8 weight portion, Radix Ginseng 2-8 weight portion, Nidus Vespae 2-15 weight portion.
Preferably, Poria 20-35 weight portion, Herba Taraxaci 10-30 weight portion, Rhizoma Atractylodis Macrocephalae 10-30 weight portion, Rhizoma Atractylodis 10-30 weight portion, Herba Pogostemonis 10-30 weight portion, Rhizoma Pinelliae Preparatum 10-30 weight portion, Pericarpium Citri Reticulatae 8-20 weight portion, Rhizoma Et Radix Notopterygii 8-20 weight portion, Rhizoma Chuanxiong 8-20 weight portion, Rhizoma Zingiberis Recens 3-6 weight portion, Radix Ginseng 3-6 weight portion, Nidus Vespae 3-10 weight portion.
Preferably, Poria 25-30 weight portion, Herba Taraxaci 15-25 weight portion, Rhizoma Atractylodis Macrocephalae 15-25 weight portion, Rhizoma Atractylodis 15-25 weight portion, Herba Pogostemonis 15-25 weight portion, Rhizoma Pinelliae Preparatum 15-25 weight portion, Pericarpium Citri Reticulatae 10-15 weight portion, Rhizoma Et Radix Notopterygii 10-15 weight portion, Rhizoma Chuanxiong 10-15 weight portion, Rhizoma Zingiberis Recens 3-5 weight portion, Radix Ginseng 3-5 weight portion, Nidus Vespae 3-8 weight portion.
Preferably, Poria 15 weight portions, Herba Taraxaci 10 weight portions, the Rhizoma Atractylodis Macrocephalae 10 weight portions, Rhizoma Atractylodis 10 weight portions, Herba Pogostemonis 10 weight portions, Rhizoma Pinelliae Preparatum 10 weight portions, Pericarpium Citri Reticulatae 5 weight portions, Rhizoma Et Radix Notopterygii 5 weight portions, Rhizoma Chuanxiong 5 weight portions, Rhizoma Zingiberis Recens 3 weight portions, Radix Ginseng 3 weight portions, Nidus Vespae 5 weight portions.
The present invention also aims to provide a kind of preparation method of preparing above-mentioned arbitrary pharmaceutical composition, it comprises the following steps:
S1: take raw material by component and weight ratio;
S2: by after raw material mix homogeneously, add pharmaceutically acceptable adjuvant to be prepared into pharmaceutically conventional pharmaceutical preparation.
Pharmaceutical composition of the present invention can be prepared into the above dosage form of any pharmaceutics according to the conventional method of pharmaceutical field; Pharmaceutical composition can be applied to patient by modes such as oral, suction or intestinal external administrations.Described pharmaceutically conventional types of drug preparations comprises: the tablet that uses when oral administration, capsule, pill, powder, granule, syrup, oral liquid etc.; The freeze-dried powder and the injection etc. that in the time of intestinal external administration, use.
Described pharmaceutic adjuvant comprises: starch, magnesium stearate, dextrin and microcrystalline Cellulose.
Above-mentioned arbitrary pharmaceutical composition is for the purposes of the medicine at preparation treatment and alleviation buccal cavity fungal infection.
Poria is the sclerotium of On Polyporaceae Poria, has the effect of promoting diuresis to eliminate damp pathogen, invigorating the spleen for dissipating phlegm, mind tranquilizing and the heart calming; Herba Taraxaci is feverfew Herba Taraxaci or the herb that belongs to several plants together, has the effect of heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, clearing away heat-damp and promoting diuresis; The Rhizoma Atractylodis Macrocephalae is the rhizome of the feverfew Rhizoma Atractylodis Macrocephalae, has air making-up and spleen enlivening, dampness diuretic, the antiabortive effect of hidroschesis; Rhizoma Atractylodis are feverfew Atractylodes lancea (Thunb.) DC. or by the rhizome of Rhizoma Atractylodis, have the effect drying damp and strengthening spleen, expelling wind and removing dampness induces sweat; Herba Pogostemonis is the aerial parts of labiate Herba Pogostemonis or Herba Pogostemonis, has the induce sweat effect of preventing or arresting vomiting of removing dampness; Rhizoma Pinelliae Preparatum is the processed product of the Rhizoma Pinelliae, and the Rhizoma Pinelliae is the tuber of the aroid Rhizoma Pinelliae, has the effect of drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI, dissolving lump and resolving mass; Pericarpium Citri Reticulatae is the mature peel of rutaceae orange and variety thereof, has the effect of regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm; Rhizoma Et Radix Notopterygii is dry rhizome and the root of samphire Rhizoma Et Radix Notopterygii or Radix et Rhizoma Notopterygii; Rhizoma Chuanxiong is the rhizome of Umbelliferae Rhizoma Chuanxiong, has the effect of blood-activating and qi-promoting, wind-expelling pain-stopping; Rhizoma Zingiberis Recens is the fresh rhizome of zingiber, has the effect of dispersing wind-cold, warming middle-JIAO to arrest vomiting, warming the lung to relieve cough; Radix Ginseng is the root of Araliaceae Radix Ginseng, has strongly invigorating primordial QI, vigorate qi and replenish the blood, the effect of the Fructus Alpiniae Oxyphyllae of calming the nerves, promoting the production of body fluid to quench thirst; Nidus Vespae is the nest of Vespidae insecticide fruit hornet, the long foot wasp of Japan or different abdomen wasp, has the effect of detoxicating and killing parasites, wind-expelling pain-stopping.
For above-mentioned dosage form can be realized, can in the time of these dosage forms of preparation, add the acceptable adjuvant of pharmacy, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, acetic acid chloroethene are determined, Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods; Substrate comprises: PEG6000, PEG4000, insect wax etc.
Pharmaceutical composition of the present invention through the beneficial effect of pharmacodynamics checking is:
Pharmaceutical composition of the present invention proves that through drug effect and clinical experimental study the funguses such as dialogue candidiasis, Candida albicans, aspergillosis, mucormycosis and cryptococcus have stronger antibacterial activity, buccal cavity fungal infection patient is had to good therapeutical effect, clinically can be widely used in buccal cavity fungal infection patient.Pharmaceutical composition of the present invention has the property taken into account preferably simultaneously, and for dyspepsia patient, especially patients with functional dyspepsia has good therapeutical effect.Pharmaceutical composition good effect of the present invention, zest are little, few side effects and drug cost cheap, be applicable to promote the use of on a large scale, there is good medical prospect.
Detailed description of the invention
Below in conjunction with specific embodiment, technical scheme of the present invention is described in further detail, but protection scope of the present invention is not limited to the following stated.
Embodiment 1
Take raw material Poria 10g, Herba Taraxaci 5g, Rhizoma Atractylodis Macrocephalae 5g, Rhizoma Atractylodis 5g, Herba Pogostemonis 5g, Rhizoma Pinelliae Preparatum 5g, Pericarpium Citri Reticulatae 3g, Rhizoma Et Radix Notopterygii 3g, Rhizoma Chuanxiong 3g, Rhizoma Zingiberis Recens 1g, Radix Ginseng 1g, Nidus Vespae 1g, add supplementary product starch 50g to granulate, magnesium stearate 5g, dextrin 25g, microcrystalline Cellulose 25g, evenly make granule, and tabletting, obtains tablet.
Embodiment 2
Take raw material Poria 15g, Herba Taraxaci 8g, Rhizoma Atractylodis Macrocephalae 8g, Rhizoma Atractylodis 8g, Herba Pogostemonis 8g, Rhizoma Pinelliae Preparatum 8g, Pericarpium Citri Reticulatae 5g, Rhizoma Et Radix Notopterygii 5g, Rhizoma Chuanxiong 5g, Rhizoma Zingiberis Recens 2g, Radix Ginseng 2g, Nidus Vespae 2g, adds supplementary product starch 70g to granulate, magnesium stearate 8g, dextrin 50g, microcrystalline Cellulose 50g, evenly makes granule, and tabletting, obtains tablet.
Embodiment 3
Take raw material Poria 20g, Herba Taraxaci 10g, Rhizoma Atractylodis Macrocephalae 10g, Rhizoma Atractylodis 10g, Herba Pogostemonis 10g, Rhizoma Pinelliae Preparatum 10g, Pericarpium Citri Reticulatae 8g, Rhizoma Et Radix Notopterygii 8g, Rhizoma Chuanxiong 8g, Rhizoma Zingiberis Recens 3g, Radix Ginseng 3g, Nidus Vespae 3g, adds supplementary product starch 90g to granulate, magnesium stearate 12g, dextrin 60g, microcrystalline Cellulose 60g, evenly make granule, tabletting, obtains tablet.
Embodiment 4
Take raw material Poria 25g, Herba Taraxaci 15g, Rhizoma Atractylodis Macrocephalae 15g, Rhizoma Atractylodis 15g, Herba Pogostemonis 15g, Rhizoma Pinelliae Preparatum 15g, Pericarpium Citri Reticulatae 10g, Rhizoma Et Radix Notopterygii 10g, Rhizoma Chuanxiong 10g, Rhizoma Zingiberis Recens 3g, Radix Ginseng 3g, Nidus Vespae 5g, adds supplementary product starch 90g to granulate, magnesium stearate 12g, dextrin 80g, microcrystalline Cellulose 80g, evenly make granule, tabletting, obtains tablet.
Embodiment 5
Take raw material Poria 15g, Herba Taraxaci 10g, Rhizoma Atractylodis Macrocephalae 10g, Rhizoma Atractylodis 10g, Herba Pogostemonis 10g, Rhizoma Pinelliae Preparatum 10g, Pericarpium Citri Reticulatae 5g, Rhizoma Et Radix Notopterygii 5g, Rhizoma Chuanxiong 5g, Rhizoma Zingiberis Recens 3g, Radix Ginseng 3g, Nidus Vespae 8g, adds supplementary product starch 80g to granulate, magnesium stearate 10g, dextrin 80g, microcrystalline Cellulose 80g, evenly make granule, tabletting, obtains tablet.
Embodiment 6
Take raw material Poria 30g, Herba Taraxaci 25g, Rhizoma Atractylodis Macrocephalae 25g, Rhizoma Atractylodis 25g, Herba Pogostemonis 25g, Rhizoma Pinelliae Preparatum 25g, Pericarpium Citri Reticulatae 15g, Rhizoma Et Radix Notopterygii 15g, Rhizoma Chuanxiong 15g, Rhizoma Zingiberis Recens 5g, Radix Ginseng 5g, Nidus Vespae 10g, add supplementary product starch 100g to granulate, magnesium stearate 12g, dextrin 100g, microcrystalline Cellulose 100g, evenly make granule, incapsulate, obtain capsule.
Embodiment 7
Take raw material Poria 40g, Herba Taraxaci 35g, Rhizoma Atractylodis Macrocephalae 35g, Rhizoma Atractylodis 35g, Herba Pogostemonis 35g, Rhizoma Pinelliae Preparatum 35g, Pericarpium Citri Reticulatae 25g, Rhizoma Et Radix Notopterygii 25g, Rhizoma Chuanxiong 25g, Rhizoma Zingiberis Recens 8g, Radix Ginseng 8g, Nidus Vespae 15g, add supplementary product starch 300g to granulate, magnesium stearate 50g, dextrin 150g, microcrystalline Cellulose 150g, evenly make granule, incapsulate, obtain capsule.
Embodiment 8
Take raw material Poria 45g, Herba Taraxaci 40g, Rhizoma Atractylodis Macrocephalae 40g, Rhizoma Atractylodis 40g, Herba Pogostemonis 40g, Rhizoma Pinelliae Preparatum 40g, Pericarpium Citri Reticulatae 30g, Rhizoma Et Radix Notopterygii 30g, Rhizoma Chuanxiong 30g, Rhizoma Zingiberis Recens 10g, Radix Ginseng 10g, Nidus Vespae 20g, add supplementary product starch 400g to granulate, magnesium stearate 60g, dextrin 200g, microcrystalline Cellulose 200g, evenly make granule, incapsulate, obtain capsule.
Embodiment 9
Take raw material Poria 10g, Herba Taraxaci 5g, Rhizoma Atractylodis Macrocephalae 5g, Rhizoma Atractylodis 5g, Herba Pogostemonis 5g, Rhizoma Pinelliae Preparatum 5g, Pericarpium Citri Reticulatae 3g, Rhizoma Et Radix Notopterygii 3g, Rhizoma Chuanxiong 3g, Rhizoma Zingiberis Recens 1g, Radix Ginseng 1g, Nidus Vespae 1g, adds conventional adjuvant according to common process, is prepared into pill.
Embodiment 10
Take raw material Poria 15g, Herba Taraxaci 8g, Rhizoma Atractylodis Macrocephalae 8g, Rhizoma Atractylodis 8g, Herba Pogostemonis 8g, Rhizoma Pinelliae Preparatum 8g, Pericarpium Citri Reticulatae 5g, Rhizoma Et Radix Notopterygii 5g, Rhizoma Chuanxiong 5g, Rhizoma Zingiberis Recens 2g, Radix Ginseng 2g, Nidus Vespae 2g, adds conventional adjuvant according to common process, is prepared into oral liquid.
Embodiment 11
Take raw material Poria 20g, Herba Taraxaci 10g, Rhizoma Atractylodis Macrocephalae 10g, Rhizoma Atractylodis 10g, Herba Pogostemonis 10g, Rhizoma Pinelliae Preparatum 10g, Pericarpium Citri Reticulatae 8g, Rhizoma Et Radix Notopterygii 8g, Rhizoma Chuanxiong 8g, Rhizoma Zingiberis Recens 3g, Radix Ginseng 3g, Nidus Vespae 5g, adds conventional adjuvant according to common process, is prepared into granule.
Embodiment 12
Take raw material Poria 25g, Herba Taraxaci 15g, Rhizoma Atractylodis Macrocephalae 15g, Rhizoma Atractylodis 15g, Herba Pogostemonis 15g, Rhizoma Pinelliae Preparatum 15g, Pericarpium Citri Reticulatae 10g, Rhizoma Et Radix Notopterygii 10g, Rhizoma Chuanxiong 10g, Rhizoma Zingiberis Recens 3g, Radix Ginseng 3g, Nidus Vespae 10g, adds conventional adjuvant according to common process, is prepared into effervescent.
Embodiment 13
Take raw material Poria 45g, Herba Taraxaci 40g, Rhizoma Atractylodis Macrocephalae 40g, Rhizoma Atractylodis 40g, Herba Pogostemonis 40g, Rhizoma Pinelliae Preparatum 40g, Pericarpium Citri Reticulatae 30g, Rhizoma Et Radix Notopterygii 30g, Rhizoma Chuanxiong 30g, Rhizoma Zingiberis Recens 10g, Radix Ginseng 10g, Nidus Vespae 15g, is prepared into decoction according to common process.
Embodiment 14
Poria 15g, Herba Taraxaci 10g, Rhizoma Atractylodis Macrocephalae 10g, Rhizoma Atractylodis 10g, Herba Pogostemonis 10g, Rhizoma Pinelliae Preparatum 10g, Pericarpium Citri Reticulatae 5g, Rhizoma Et Radix Notopterygii 5g, Rhizoma Chuanxiong 5g, Rhizoma Zingiberis Recens 3g, Radix Ginseng 3g, Nidus Vespae 5g, is prepared into decoction according to common process.
Test to prove beneficial effect of the present invention below by concrete clinical research:
1 clinical research data
1.1 case sources
Select the court buccal cavity fungal infection case, age 18-60 year, 32 of men, 55 of female, all cases all meets inclusion criteria.
1.2 inclusive criteria
(1) throat swab fungal culture experiment positive patient; (2) accept voluntarily this experiment and adhered to person's course for the treatment of; (3) without severe cardiac, liver, renal dysfunction patient.
1.3 exclusion standard
(1) do not meet above-mentioned inclusive criteria person; (2) cannot carry out oral cavity medicine patient; (3) allergic constitution or to multi-medicament autopath.
1.4 rejecting standards
(1) do not use Experimental agents person by this experimental technique; (2) in therapeutic process, use two or more mouthwash solution persons simultaneously; (3) treatment is the nature person of coming off less than drug treatment.
2 methods of clinical observation
2.1 experiment grouping and Therapeutic Method
Screening meets 87 patients that include exclusion standard in and divides into groups by table of random number, is divided into experimental group and positive controls.Experimental group Chinese medicine formula: Poria 15g, Herba Taraxaci 10g, Rhizoma Atractylodis Macrocephalae 10g, Rhizoma Atractylodis 10g, Herba Pogostemonis 10g, Rhizoma Pinelliae Preparatum 10g, Pericarpium Citri Reticulatae 5g, Rhizoma Et Radix Notopterygii 5g, Rhizoma Chuanxiong 5g, Rhizoma Zingiberis Recens 3g, Radix Ginseng 3g, Nidus Vespae 5g(is the dosage ratio of embodiment 14).Every dose decocts 15 minutes, decocts 2 times, is made into decoction, is concentrated into 100ml, and every bu is gargled for 3 times, each 30ml, each rinsing the mouth medicinal liquid 5mim.Positive controls adopts Chlorhexidine Compound Mouthrinse Solution, and Jiangsu Chenpai Pharmaceutical Co., Ltd produces, specification 150ml/ bottle, and every bu is gargled for 3 times, each 30ml, each rinsing the mouth medicinal liquid 5mim, two groups of patient's continuous uses 10 days are 1 course for the treatment of.
2.2 observation index
The full fungal culture such as candida albicans bacterium, gram Rou Shi candidiasis, Candida glabrata and Candida albicans of carrying out after 7 days and 10 days of medication detect, and it is effectively that throat swab is cultivated negative (-) patient, and it is invalid that throat swab is cultivated positive (+) patient.Oropharyngeal swab specimen is gathered by special messenger and is operated to cultivate by the Bacteriology Room special messenger of the court and measures.
2.3 statistical method
Adopt SPSS13.0 statistical software to analyze, enumeration data adopts X 2 test, and measurement data adopts t inspection, relatively adopts one factor analysis of variance between group, has statistical significance taking P<0.05 as difference.
3 experimental results
Treat after 7 days, treatment group fungus negative conversion rate is: 65.12%, and positive controls fungus negative conversion rate is: 47.73%; Both relatively have statistical significance, the results are shown in Table 1.Treat after 10 days, treatment group fungus negative conversion rate is: 72.09%, and positive controls fungus negative conversion rate is: 68.18%; Both compare not statistically significant, in table 2.Experimental result shows that the therapeutical effect after 7 days is better than positive controls to pharmaceutical composition of the present invention in medication, there is statistical significance, but continuous use after 10 days the therapeutical effect for the treatment of group and the therapeutical effect of positive controls approach, there was no significant difference, shows that pharmaceutical composition of the present invention curative effect is in a short time better than positive controls.
Table 1 liang group medication fungus negative conversion rate comparison after 7 days
Table 2 liang group medication fungus negative conversion rate comparison after 10 days
In addition, show by In Vitro Anti aspergillosis, mucormycosis and cryptococcus test, pharmaceutical composition of the present invention has stronger inhibitory action to above-mentioned fungus strain.
Adopt the mature animal model folder tail method of fighting, and share on this basis irregular nursing and hot and cold water and feed the intermingling cold and heat functional dyspepsia rat model modeling of comprehensive modeling.After modeling finishes by the common dose drug treatment of pharmaceutical composition of the present invention (dosage ratio of embodiment 14) 7 days, adopt cisapride to compare, result shows pharmaceutical composition of the present invention can significantly raise rat plasma motilin, gastrin content, also can effectively improve the objective indicators such as serum acetylcholine, acetylcholinesterase and acetylcholine transferase, curative effect and positive controls are comparatively approaching simultaneously.
In sum, pharmaceutical composition of the present invention has stronger inhibitory action to oral cavity fungus, clinically can be widely used in buccal cavity fungal infection patient, pharmaceutical composition of the present invention is for dyspepsia patient simultaneously, and especially patients with functional dyspepsia has good therapeutical effect.
Claims (9)
1. a pharmaceutical composition for the treatment of buccal cavity fungal infection, is characterized in that: it is made up of following raw material and weight ratio:
Poria 10-45 weight portion, Herba Taraxaci 5-40 weight portion, Rhizoma Atractylodis Macrocephalae 5-40 weight portion, Rhizoma Atractylodis 5-40 weight portion, Herba Pogostemonis 5-40 weight portion, Rhizoma Pinelliae Preparatum 5-40 weight portion, Pericarpium Citri Reticulatae 3-30 weight portion, Rhizoma Et Radix Notopterygii 3-30 weight portion, Rhizoma Chuanxiong 3-30 weight portion, Rhizoma Zingiberis Recens 1-10 weight portion, Radix Ginseng 1-10 weight portion, Nidus Vespae 1-20 weight portion.
2. a kind of pharmaceutical composition for the treatment of buccal cavity fungal infection according to claim 1, is characterized in that: the ratio of weight and number of described each raw material is: Poria 15-40 weight portion, Herba Taraxaci 8-35 weight portion, Rhizoma Atractylodis Macrocephalae 8-35 weight portion, Rhizoma Atractylodis 8-35 weight portion, Herba Pogostemonis 8-35 weight portion, Rhizoma Pinelliae Preparatum 8-35 weight portion, Pericarpium Citri Reticulatae 5-25 weight portion, Rhizoma Et Radix Notopterygii 5-25 weight portion, Rhizoma Chuanxiong 5-25 weight portion, Rhizoma Zingiberis Recens 2-8 weight portion, Radix Ginseng 2-8 weight portion, Nidus Vespae 2-15 weight portion.
3. a kind of pharmaceutical composition for the treatment of buccal cavity fungal infection according to claim 1, is characterized in that: the ratio of weight and number of described each raw material is: Poria 20-35 weight portion, Herba Taraxaci 10-30 weight portion, Rhizoma Atractylodis Macrocephalae 10-30 weight portion, Rhizoma Atractylodis 10-30 weight portion, Herba Pogostemonis 10-30 weight portion, Rhizoma Pinelliae Preparatum 10-30 weight portion, Pericarpium Citri Reticulatae 8-20 weight portion, Rhizoma Et Radix Notopterygii 8-20 weight portion, Rhizoma Chuanxiong 8-20 weight portion, Rhizoma Zingiberis Recens 3-6 weight portion, Radix Ginseng 3-6 weight portion, Nidus Vespae 3-10 weight portion.
4. a kind of pharmaceutical composition for the treatment of buccal cavity fungal infection according to claim 1, is characterized in that: the ratio of weight and number of described each raw material is: Poria 25-30 weight portion, Herba Taraxaci 15-25 weight portion, Rhizoma Atractylodis Macrocephalae 15-25 weight portion, Rhizoma Atractylodis 15-25 weight portion, Herba Pogostemonis 15-25 weight portion, Rhizoma Pinelliae Preparatum 15-25 weight portion, Pericarpium Citri Reticulatae 10-15 weight portion, Rhizoma Et Radix Notopterygii 10-15 weight portion, Rhizoma Chuanxiong 10-15 weight portion, Rhizoma Zingiberis Recens 3-5 weight portion, Radix Ginseng 3-5 weight portion, Nidus Vespae 3-8 weight portion.
5. a kind of pharmaceutical composition for the treatment of buccal cavity fungal infection according to claim 1, is characterized in that: the ratio of weight and number of described each raw material is: Poria 15 weight portions, Herba Taraxaci 10 weight portions, the Rhizoma Atractylodis Macrocephalae 10 weight portions, Rhizoma Atractylodis 10 weight portions, Herba Pogostemonis 10 weight portions, Rhizoma Pinelliae Preparatum 10 weight portions, Pericarpium Citri Reticulatae 5 weight portions, Rhizoma Et Radix Notopterygii 5 weight portions, Rhizoma Chuanxiong 5 weight portions, Rhizoma Zingiberis Recens 3 weight portions, Radix Ginseng 3 weight portions, Nidus Vespae 5 weight portions.
6. a method of preparing the pharmaceutical composition of the treatment buccal cavity fungal infection described in any one claim in claim 1～5, is characterized in that: it comprises the following steps:
S1: take raw material by component and weight ratio;
S2: by after raw material mix homogeneously, add pharmaceutically acceptable adjuvant to be prepared into pharmaceutically conventional pharmaceutical preparation.
7. the preparation method of a kind of pharmaceutical composition for the treatment of buccal cavity fungal infection according to claim 6, is characterized in that: described pharmaceutical preparation is tablet, capsule, granule, pill, powder or oral liquid.
8. the preparation method of a kind of pharmaceutical composition for the treatment of buccal cavity fungal infection according to claim 6, is characterized in that: described pharmaceutically acceptable adjuvant comprises starch, magnesium stearate, dextrin and microcrystalline Cellulose.
9. the purposes of the pharmaceutical composition as described in any one claim in claim 1～5 in preparation treatment buccal cavity fungal infection medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410069103.3A CN103800885B (en) | 2014-02-27 | 2014-02-27 | Medicinal composition for treating oral fungal infection, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410069103.3A CN103800885B (en) | 2014-02-27 | 2014-02-27 | Medicinal composition for treating oral fungal infection, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103800885A CN103800885A (en) | 2014-05-21 |
| CN103800885B true CN103800885B (en) | 2014-11-05 |
Family
ID=50698579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410069103.3A Expired - Fee Related CN103800885B (en) | 2014-02-27 | 2014-02-27 | Medicinal composition for treating oral fungal infection, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103800885B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112999177A (en) * | 2021-01-30 | 2021-06-22 | 成都大学 | Chinese herbal medicine bacteriostatic effervescent tablet containing ligusticum wallichii extract and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239119A (en) * | 2008-03-13 | 2008-08-13 | 张旭明 | Chinese herbal medicine oral liquid formulations for treating intractable oral ulcer and halitosis |
-
2014
- 2014-02-27 CN CN201410069103.3A patent/CN103800885B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103800885A (en) | 2014-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100998851A (en) | Chinese medicinal preparation for curriculum of physical and fatigue reducing | |
| CN100502936C (en) | Chinese medicinal compound preparation for inhibiting tumor and resisting insenescence | |
| CN104257704A (en) | Novel application of eurycoma longifolia extracts | |
| CN103977314A (en) | Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition | |
| CN101810337A (en) | Health food containing pseudo-ginseng and ganoderma lucidum and radix astragali | |
| CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN103800885B (en) | Medicinal composition for treating oral fungal infection, preparation method and application thereof | |
| CN103961614A (en) | Traditional Chinese medicine composition for treating respiratory system diseases as well as preparation method and application thereof | |
| CN105395600A (en) | Application of cyclocarya paliurus extract in preparing medicine for treating cardiovascular and cerebrovascular diseases | |
| CN1985944A (en) | Chinese medicine composition for treating cutaneous pruritus, rubella and other diseases | |
| CN101904935A (en) | Chinese medicinal composition for improving immunity of organisms, tonifying middle-jiao and qi and treating canine distemper | |
| CN111358906B (en) | Traditional Chinese medicine composition suitable for exogenous diseases | |
| CN105381406A (en) | Traditional Chinese medicine preparation for treating lung cancer and preparation method thereof | |
| CN103830651B (en) | Oral cavity fungistat and preparation method thereof | |
| CN103768454B (en) | A kind of composition with prevention and treatment HIV/AIDS and preparation method thereof | |
| CN105250549A (en) | Traditional Chinese medicine composition for relieving sequela of apoplexy | |
| CN104189770A (en) | Pharmaceutical composition for treating tuberculous pleuritis and preparation method thereof | |
| CN104173830A (en) | Medicament for reconciling interior syndromes and relieving exterior syndromes for high fever of cold in winter and preparation method thereof | |
| CN104055886A (en) | Medicinal composition for treating chronic cough, and preparation method and application thereof | |
| CN104524187B (en) | A kind of Chinese medicine preparation for the treatment of laryngopharynx swelling and pain and preparation method thereof | |
| CN103405723B (en) | Medicine composition for treating recurrent respiratory tract infection of children | |
| CN102133332B (en) | Traditional Chinese medicine compound preparation for preventing and curing coronary heart disease and angina and preparation method thereof | |
| CN102429946B (en) | Chinese medicinal composition for preparing anti-influenza virus medicament | |
| CN102178757B (en) | Medicinal composition containing ferment caterpillar fungus powder and pears serving as raw materials | |
| CN101721437A (en) | Medicine composition used for treating chronic pharyngitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141105 Termination date: 20180227 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |